Novo Nordisk Gives Uninspiring Outlook
Summary
Parkev provides an analysis of Novo Nordisk's long-term outlook, highlighting management's forecast of mid-single-digit revenue growth through 2030. Parkev points out that investor disappointment stems from patent expirations in the weight-loss category and a declining trend in return on invested capital, which has dropped from 80-90% to the high 30s. Parkev notes that the company is undertaking cost-cutting measures, including 12,000 layoffs, to fund research and development. Using a discounted cash flow model, Parkev calculates a fair value of $64.50, suggesting a 68% upside, but Parkev expresses waning confidence in the stock compared to competitors.
Mentioned Stocks
Reasoning: Parkev recommends Eli Lilly as a better alternative to Novo Nordisk, citing stronger performance and a better position in the weight-loss market. Parkev prefers the risk-reward profile of Eli Lilly despite personally owning the stock. Parkev believes the investment strategy and market execution make Eli Lilly a more attractive buy for investors.
Reasoning: Parkev maintains a buy rating for Novo Nordisk based on a discounted cash flow valuation of $64.50, which implies 68% upside from the current market price of $38.36. Parkev notes that the stock is trading at a historically low forward P/E of 11.3. Parkev has lowered confidence in the stock to a low level because management's 2030 growth projections were lower than expected and return on invested capital is trending downward.